MaxCyte Inc Overview
Industry: Medical Devices
Sector: Healthcare
MaxCyte, Inc., a global life sciences company, discovers, develops, and commercializes next-generation cell therapies. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland. MaxCyte, Inc., a global life sciences company, discovers, develops, and commercializes next-generation cell therapies. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and Read MoreMavefund brings filings, fundamentals, valuation, price history and news for MaxCyte Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $3.4M (+62% YoY). Net loss was -$4.8M (from $10.3M). Cash was $147.7M.
Revenue
$3.4M
+62% YoY
Net loss
-$4.8M
from $10.3M
Cash
$147.7M
reported
What changed
- Revenue +62% YoY to $3.4M.
- Net loss was -$4.8M (from $10.3M).
Guidance / outlook
The Company expects to utilize a majority of the approved $10 million in the short to medium term, however, the amount and timing of any repurchases made under the repurchase program will depend on a variety of factors, including available liquidity, cash flow and market conditions.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
May 13, 2026
Earnings material
Earnings release
May 12, 2026
SEC filing
8-K
May 12, 2026
SEC filing
10-K
Mar 25, 2026
Earnings release
Earnings release
Mar 24, 2026
Earnings material
Earnings release
Mar 24, 2026
SEC filing
8-K
Mar 24, 2026
SEC filing
8-K
Jan 12, 2026
Earnings release
Earnings release
Jan 12, 2026
SEC filing
10-Q
Nov 13, 2025
Earnings material
Earnings release
Nov 12, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
MaxCyte stock surges on Genentech technology license deal
Headline from Investing.com: MaxCyte stock surges on Genentech technology license deal.
Genentech licenses MaxCyte cell engineering technology
Headline from Investing.com: Genentech licenses MaxCyte cell engineering technology.
Earnings Per Share
Score 1.00/5
MaxCyte Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Medical Devices industry
, Abbott Laboratories
, DexCom Inc
, Edwards Lifesciences Corp
are companies with high ratings.
Return on Equity
Score 1.95/5
MaxCyte Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 0.76/5
MaxCyte Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 3.61/5
MaxCyte Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios